Are some patients with hepatocellular carcinoma just too old to be treated? More specifically, should the age of a patient influence the way sorafenib is prescribed? A new study has tried to address these questions, providing helpful information to guide clinicians making these decisions
Background: HCC accounts for approximately 90% of all primary liver cancers, and is the fifth most c...
hepatocellular carcinoma (HCC) until 2007, when a large randomized trial with sorafenib demonstrated...
Sorafenib is considered the standard systemic therapy for hepatocellular carcinoma (HCC), in patient...
Background: There is no consensus on the effect of sorafenib dosing on efficacy and toxicity in elde...
The treatment of hepatocellular carcinoma (HCC) in elderly patients is unclear. In particular, the e...
Background. With the aging population, hepatocellular carcinoma (HCC) in the elderly represents a si...
International audiencePURPOSE: Sorafenib is the standard of care for advanced hepatocellular carcino...
OBJECTIVES: To evaluate the efficacy and safety of sorafenib in elderly patients with advanced hepat...
interests; (IP) Intellectual property rights/inventor/patent holder Background. With the aging popul...
AIMS:This retrospective study was carried out to compare the outcomes between elderly (≥70 years of ...
Aims This retrospective study was carried out to compare the outcomes between elderly (>= 70 y...
<p><strong>Background.</strong> The perception that older cancer patients may be at higher risk than...
Aims This retrospective study was carried out to compare the outcomes between elderly (70 years of a...
Background: HCC accounts for approximately 90% of all primary liver cancers, and is the fifth most c...
Background: Upon FDA/EMEA registration for hepatocellular carcinoma (HCC), sorafenib received a broa...
Background: HCC accounts for approximately 90% of all primary liver cancers, and is the fifth most c...
hepatocellular carcinoma (HCC) until 2007, when a large randomized trial with sorafenib demonstrated...
Sorafenib is considered the standard systemic therapy for hepatocellular carcinoma (HCC), in patient...
Background: There is no consensus on the effect of sorafenib dosing on efficacy and toxicity in elde...
The treatment of hepatocellular carcinoma (HCC) in elderly patients is unclear. In particular, the e...
Background. With the aging population, hepatocellular carcinoma (HCC) in the elderly represents a si...
International audiencePURPOSE: Sorafenib is the standard of care for advanced hepatocellular carcino...
OBJECTIVES: To evaluate the efficacy and safety of sorafenib in elderly patients with advanced hepat...
interests; (IP) Intellectual property rights/inventor/patent holder Background. With the aging popul...
AIMS:This retrospective study was carried out to compare the outcomes between elderly (≥70 years of ...
Aims This retrospective study was carried out to compare the outcomes between elderly (>= 70 y...
<p><strong>Background.</strong> The perception that older cancer patients may be at higher risk than...
Aims This retrospective study was carried out to compare the outcomes between elderly (70 years of a...
Background: HCC accounts for approximately 90% of all primary liver cancers, and is the fifth most c...
Background: Upon FDA/EMEA registration for hepatocellular carcinoma (HCC), sorafenib received a broa...
Background: HCC accounts for approximately 90% of all primary liver cancers, and is the fifth most c...
hepatocellular carcinoma (HCC) until 2007, when a large randomized trial with sorafenib demonstrated...
Sorafenib is considered the standard systemic therapy for hepatocellular carcinoma (HCC), in patient...
DOI
Add to ORKG